{"id":1006123,"date":"2026-09-28T07:17:30","date_gmt":"2026-09-28T11:17:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\/"},"modified":"2026-09-28T07:17:30","modified_gmt":"2026-09-28T11:17:30","slug":"blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\/","title":{"rendered":"BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND submission in Q1 2027<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Novel Switch-II scaffold and pseudo-irreversible binding designed to enable prolonged, potent and selective inhibition of mutant KRAS to potentially achieve improved efficacy and tolerability<\/em>\n      <\/p>\n<p>SAN DIEGO, Sept.  28, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yVSdWnXKGlDXyM8mlfManCdcF5FXi7CABa6iiCwZ05V_dZPduu3vFt5OlOx_R04PqVUIHZdNYgztKQ_PJSrHv6CR4kengK9PcV-KYQUndh7AKh3xjbtvxK3W-xYt2268\" rel=\"nofollow\" target=\"_blank\"><u>BlossomHill Therapeutics, Inc.<\/u><\/a> (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced the presentation of preclinical data on BH-501284 at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development, taking place September 25-28, 2026, in San Diego, CA. BH-501284 is a novel, orally bioavailable, non-covalent, pseudo-irreversible pan-KRAS inhibitor designed to overcome limitations of current KRAS-targeted therapies.<\/p>\n<p>\u201c<em>KRAS<\/em> mutation has historically been one of the most challenging oncogenic drivers to target, and while recent advances have validated its therapeutic potential, we believe there remains an opportunity to develop a pan-KRAS inhibitor capable of delivering potent and durable target inhibition across a broad range of <em>KRAS<\/em> mutations,\u201d said Jean Cui, Ph.D., Founder and Chief Executive Officer of BlossomHill Therapeutics. \u201cWe designed BH-501284 with a novel Switch-II chemical scaffold and pseudo-irreversible binding characteristics intended to achieve prolonged, potent and selective inhibition of <em>KRAS<\/em> mutations, which we believe may result in improved efficacy and tolerability. These preclinical data demonstrate sustained KRAS pathway suppression, and deep and durable antitumor activity across multiple <em>KRAS<\/em>-mutant tumor models, further supporting the advancement of BH-501284 toward an IND submission in Q12027.\u201d<\/p>\n<p>\n        <strong>Presentation highlights: <\/strong>\n      <\/p>\n<ul>\n<li style=\"text-align:left\">\n          <strong>BH-501284 exhibited potent and prolonged activity across a broad range of <\/strong><br \/>\n          <strong><br \/>\n            <em>KRAS<\/em><br \/>\n          <\/strong><br \/>\n          <strong> mutations. <\/strong>BH-501284 showed a target residence time of more than 54 hours in a SPR study using GDP- state KRAS G12D protein, extended KRAS signaling inhibition in <em>KRAS<\/em>-mutant cell lines, and potent cellular activity across multiple <em>KRAS<\/em> mutations, while sparing HRAS and NRAS.<\/li>\n<li style=\"text-align:left\">\n          <strong>BH-501284 showed deep and durable antitumor activity across multiple preclinical <\/strong><br \/>\n          <strong><br \/>\n            <em>KRAS<\/em><br \/>\n          <\/strong><br \/>\n          <strong>-mutant tumor models. <\/strong>Treatment resulted in tumor regression across pancreatic, lung and colorectal cancer models with <em>KRAS<\/em> G12V, D or C mutation at relatively low doses. In a KRAS G12C lung cancer model, pseudo-irreversible BH-501284 achieved tumor regression comparable to covalent, irreversible KRAS G12C inhibitors.<\/li>\n<li style=\"text-align:left\">\n          <strong>BH-501284 demonstrated deeper and more durable tumor regression than tricomplex RAS inhibitors.<\/strong> In a KRAS G12D pancreatic cancer model, BH-501284 achieved deeper and more durable tumor regression than tricomplex inhibitors when administered at similar doses.<\/li>\n<li style=\"text-align:left\">\n          <strong>BH-501284 also demonstrated the potential to combine with an anti-PD-1 treatment. <\/strong>In a KRAS G12D colorectal cancer model, the combination demonstrated prolonged survival compared with either treatment alone.<\/li>\n<\/ul>\n<p>\n        <strong>About BH-50<\/strong><br \/>\n        <strong>1284<\/strong><br \/>\n        <br \/>BH-501284 is an investigational, orally bioavailable pan-KRAS inhibitor, which utilizes a novel Switch-II chemical scaffold to achieve prolonged, potent and selective inhibition of <em>KRAS<\/em> mutations. We believe this molecule, which uses a non-covalent scaffold, is unique in its potential to achieve tight and durable binding, a feature described as \u201cpseudo-irreversible\u201d binding. In preclinical studies, BH-501284 demonstrated sustained blocking of KRAS signaling leading to deeper and more durable antitumor activities in <em>KRAS<\/em> mutant cells and tumor models at low dose levels.<\/p>\n<p>\n        <strong>About BlossomHill Therapeutics<\/strong><br \/>\n        <br \/>BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. Founded and led by industry veteran J. Jean Cui, Ph.D., with her proven track record in oncology drug design and development \u2013 including three FDA-approved drugs \u2013 BlossomHill Therapeutics applies cutting-edge science with a goal to address key oncogenic drivers and improve patient outcomes in difficult-to-treat cancers. The company\u2019s lead clinical program is BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR\u2122\u00a0inhibitor for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), which has received Fast Track designation for the C797S resistance population after 3rd generation EGFR TKI treatment. The company is also conducting clinical development of BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor initially being studied in a clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (R\/R AML) and higher-risk myelodysplastic syndromes (HR-MDS). The company\u2019s pipeline also includes BH-501284, a preclinical, non-covalent, selective, pan-KRAS Switch-II inhibitor for potential future development in diverse KRAS-mutant tumors.<\/p>\n<p>BlossomHill Therapeutics is headquartered in San Diego, California. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=slTAEOTaZVauq_5HC5chDMJG4OJvdzEcNEcxx9w7Qng3CGAF9KZvnrDUvW_y9sjfTED4o0pZ60eaS0fBSIYoJfirOdtu8QxguoFej8MiZBw=\" rel=\"nofollow\" target=\"_blank\"><u>bhtherapeutics.com<\/u><\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZSJcob9rQs-cmG4kMJkK44uV4a12T8FxA2i9e8VrnwrhVI2zhcagfbCjt8FnJNqykzxYE5UJEV6vlXRHi1mmm_TylMzd3RVYQheCL9oBm6knacVvjKbKZXDc-XWQtkKhwHXM5FlWPGaRijjGZ_s7n-14i4O3cVrzEl99A8CN81o=\" rel=\"nofollow\" target=\"_blank\"><u>LinkedIn<\/u><\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tK_DSY1PVUOUBN0C5ThKyEzW0U7zpdfw__rk7EIjrTCSwOHMFWE2d1Ygg0HxBnvnCc_K2HW_2kHCIyvD-ksxGQ==\" rel=\"nofollow\" target=\"_blank\"><u>X<\/u><\/a>.<\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements <\/strong><br \/>\n        <br \/>\n        <em>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws, including, without limitation, statements regarding: the therapeutic potential, clinical benefits, safety and potential competitive differentiation of the company\u2019s product candidates, including BH-30643, BH-30236 and BH-501284; the design, enrollment, timing, progress and results of the company\u2019s clinical trials and preclinical studies; the company\u2019s planned regulatory interactions and submissions; anticipated program milestones, including the timing of program and data updates; statements by the company\u2019s management; and the company\u2019s development plans and continued advancement of its pipeline. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cupcoming,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.<\/em>\n      <\/p>\n<p>\n        <em>Any forward-looking statements in this press release are based on management\u2019s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially, including, without limitation: the company\u2019s limited operating history, history of significant losses and the early stage of development of its product candidates; the risk that preclinical data may not be predictive of results in clinical trials; the risk that preliminary and interim clinical data are subject to further analysis and may not be predictive of, may be inconsistent with, or may be more favorable than, data generated as clinical trials continue or data from future clinical trials; uncertainties inherent in the initiation, timing, design and enrollment of clinical trials, and the availability and timing of data from ongoing and future trials; the company\u2019s ability to successfully demonstrate the safety and efficacy of its product candidates and to obtain and maintain regulatory approvals; the timing and outcome of planned interactions with, and submissions to, the FDA and other regulatory authorities, including whether an accelerated approval pathway will be available to the company; competition from third parties that are developing products for similar indications; the prior success of the company\u2019s management team not being indicative of future success; the company\u2019s reliance on third parties, including contract research organizations and contract manufacturing organizations; the company\u2019s ability to obtain, maintain and protect its intellectual property; and the company\u2019s need for additional financing and its estimates regarding operating expenses and capital requirements. These and other risks are described in greater detail under the heading \u201cRisk Factors\u201d in the company\u2019s filings with the Securities and Exchange Commission (the \u201cSEC\u201d), including the company\u2019s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as well as in the company\u2019s subsequent filings with the SEC. Any forward-looking statements represent the company\u2019s views only as of the date of this press release, and the company expressly disclaims any obligation to update any forward-looking statements, except as required by law.<\/em>\n      <\/p>\n<p>\n        <strong>Company Contact: <\/strong><br \/>\n        <br \/>Michael Moore, BlossomHill Therapeutics<br \/>michael.moore@bhtherapeutics.com<\/p>\n<p>\n        <strong>Media: <\/strong><br \/>\n        <br \/>Ashlea Kosikowski, 1AB <br \/>ashlea@1abmedia.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDY1NSM3ODY1NzAyIzIyMDc1NTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjgzODQ2ZjktYjhlNS00NTM4LWI4ZmYtNTNjYjg3NzBkMDllLTEyMTkxMDYtMjAyNi0wOS0yOC1lbg==\/tiny\/BlossomHill-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND submission in Q1 2027 Novel Switch-II scaffold and pseudo-irreversible binding designed to enable prolonged, potent and selective inhibition of mutant KRAS to potentially achieve improved efficacy and tolerability SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) &#8212; BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced the presentation of preclinical data on BH-501284 at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development, taking place September 25-28, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1006123","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND submission in Q1 2027 Novel Switch-II scaffold and pseudo-irreversible binding designed to enable prolonged, potent and selective inhibition of mutant KRAS to potentially achieve improved efficacy and tolerability SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) &#8212; BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced the presentation of preclinical data on BH-501284 at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development, taking place September 25-28, &hellip; Continue reading &quot;BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-28T11:17:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDY1NSM3ODY1NzAyIzIyMDc1NTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer\",\"datePublished\":\"2026-09-28T11:17:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\\\/\"},\"wordCount\":1262,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNDY1NSM3ODY1NzAyIzIyMDc1NTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\\\/\",\"name\":\"BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNDY1NSM3ODY1NzAyIzIyMDc1NTM=\",\"datePublished\":\"2026-09-28T11:17:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNDY1NSM3ODY1NzAyIzIyMDc1NTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNDY1NSM3ODY1NzAyIzIyMDc1NTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\/","og_locale":"en_US","og_type":"article","og_title":"BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer - Market Newsdesk","og_description":"Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND submission in Q1 2027 Novel Switch-II scaffold and pseudo-irreversible binding designed to enable prolonged, potent and selective inhibition of mutant KRAS to potentially achieve improved efficacy and tolerability SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) &#8212; BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced the presentation of preclinical data on BH-501284 at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development, taking place September 25-28, &hellip; Continue reading \"BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-28T11:17:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDY1NSM3ODY1NzAyIzIyMDc1NTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer","datePublished":"2026-09-28T11:17:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\/"},"wordCount":1262,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDY1NSM3ODY1NzAyIzIyMDc1NTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\/","name":"BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDY1NSM3ODY1NzAyIzIyMDc1NTM=","datePublished":"2026-09-28T11:17:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDY1NSM3ODY1NzAyIzIyMDc1NTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNDY1NSM3ODY1NzAyIzIyMDc1NTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-presents-preclinical-data-on-novel-pan-kras-inhibitor-bh-501284-at-the-aacr-conference-on-pancreatic-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1006123"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006123\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1006123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1006123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1006123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}